Bergquist JR, et al. - The benefit of post-resection adjuvant systemic chemotherapy alone in T2 or greater gallbladder carcinoma (GBCA) utilising a large national dataset was determined. In patients with T2 or greater GBCA with node-positive disease, adjuvant systemic chemotherapy was associated with survival benefit. A multidisciplinary approach was recommended for these patients as less than 25 percent currently receive adjuvant chemotherapy.